Urine GALNT7 had slightly improved accuracy over serum PSA at identifying men with prostate cancer within the same cohort (serum PSA: AUC 0.69, urine GALNT7: AUC 0.73), whereas combining PSA and GALNT7 further increased diagnostic accuracy (PSA + GALNT7: AUC 0.76) (Fig. 2E and Supplementary Fig. 3B). This evidence concerns the gene GALNT7 and prostate cancer.